These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29047111)

  • 1. Primary cutaneous aggressive epidermotropic cytotoxic CD8
    Cyrenne BM; Subtil A; Girardi M; Foss F
    Int J Dermatol; 2017 Dec; 56(12):1448-1450. PubMed ID: 29047111
    [No Abstract]   [Full Text] [Related]  

  • 2. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
    Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
    Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
    [No Abstract]   [Full Text] [Related]  

  • 3. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
    Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
    Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
    Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
    [No Abstract]   [Full Text] [Related]  

  • 5. Brentuximab induced CD30
    Nikolaou V; Iliakis T; Marinos L; Economidi A; Panayiotidis P; Rigopoulos D; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e147-e148. PubMed ID: 30520137
    [No Abstract]   [Full Text] [Related]  

  • 6. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):12-4. PubMed ID: 24852791
    [No Abstract]   [Full Text] [Related]  

  • 8. CD4/CD8 double-negative T-cell lymphoma: a variant of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma?
    Miyauchi T; Abe R; Morita Y; Adachi M; Shiba K; Hamade Y; Saito N; Nishimura M; Ibata M; Okada K; Shigematsu A; Endo T; Kawai K; Teshima T; Shimizu H
    Acta Derm Venereol; 2015 Nov; 95(8):1024-5. PubMed ID: 25792011
    [No Abstract]   [Full Text] [Related]  

  • 9. [Facial ulcerated nodules revealing primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma].
    Rolland M; Dinulescu M; Saillard C; Battistella M; Le Gall F; Lhomme F; Gangneux JP; Dupuy A; Adamski H
    Ann Dermatol Venereol; 2020 Nov; 147(11):764-768. PubMed ID: 32527516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.
    Lewis DJ; Talpur R; Huen AO; Tetzlaff MT; Duvic M
    JAMA Dermatol; 2017 Dec; 153(12):1302-1306. PubMed ID: 28980004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.
    Saulite I; Guenova E; Hoetzenecker W
    Curr Probl Dermatol; 2018; 53():70-81. PubMed ID: 29131039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma with a chronic and indolent course. Is this different from peripheral T cell lymphoma?
    Gomez Vazquez M; Navarra Amayuelas R
    Dermatol Online J; 2012 Mar; 18(3):11. PubMed ID: 22483522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.
    Henderson Berg MH; Davison K; Popradi G
    Br J Dermatol; 2022 Feb; 186(2):379-381. PubMed ID: 34608632
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycosis fungoides: successful re-treatment with brentuximab vedotin.
    James M; Nakamura M; Whittaker S; Morris S
    Br J Dermatol; 2024 May; 190(6):929-930. PubMed ID: 38470968
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
    Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
    Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aggressive T cytotoxic CD8+ epidermotropic cutaneous lymphoma: a case in a patient with Steinert's myotonic dystrophy].
    Du-Thanh A; Durand L; Costes V; Guillot B; Dereure O
    Ann Dermatol Venereol; 2006 Dec; 133(12):991-4. PubMed ID: 17185931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary cutaneous aggressive epidermotropic cytotoxic CD8 positive T cell lymphoma: report of one case].
    Intriago B M; Peña O C; Gray H AM; Cabrera C ME; Martínez C V
    Rev Med Chil; 2012 Mar; 140(3):368-72. PubMed ID: 22689119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.